Rigakafin thrombus yada mataki

Babu shakka cewa ci gaban anticoagulants ya inganta maganin DVT kai tsaye.Magungunan maganin rigakafi na iya hana faruwar thrombus, hana yaduwar thrombus, sauƙaƙe autolysis na thrombus da recanalization na lumen, rage alamun bayyanar cututtuka, da rage yawan abin da ya faru da mace-mace na huhu.A halin yanzu, magungunan anticoagulant sun hada da heparin, heparin low-molecular weight, warfarin, rivaroxaban da dabigatran.Kowanne daga cikin wadannan magungunan yana da nasa amfani da rashin amfani.Idan aka kwatanta da heparin mara lalacewa, ƙananan nauyin kwayoyin heparin a cikin ƙasa ko ta hanyar jijiya na iya rage yawan mace-mace.Daga cikin magungunan kashe kwayoyin cuta na baka, ana amfani da warfarin sosai saboda ƙarancin farashinsa, ingantaccen tasirin maganin jijiyoyi a cikin ingantacciyar kewayon jiyya (yana buƙatar daidaita daidaitaccen rabo na duniya ya kasance tsakanin 2 da 3).Duk da haka, saboda warfarin yana shafar abinci sosai, yana da sauƙi a sami matsaloli kamar rashin isasshen maganin jini da zubar jini, kuma ya zama dole a kula da aikin coagulation akai-akai.A cikin 'yan shekarun nan, yawancin sababbin magungunan rigakafi sun bayyana a cikin gado, irin su rivaroxaban, dabigatran, apixaban, da dai sauransu. tasirin maganin rigakafi daidai ne, matsalolin zubar da jini yana raguwa, kuma babu buƙatar sake duba aikin coagulation.

A halin yanzu, wasu masana sun ba da shawarar cewa za a iya raba maganin miyagun ƙwayoyi zuwa matakai biyu bisa ga lokacin rabon watanni 3: matakin farko ana kiransa matakin jiyya na farko.Ana aiwatar da shi ne a cikin watanni 3 bayan farawa na farko na dvt3, kuma mataki na biyu ana kiran shi matakin rigakafin sake dawowa, wanda ake yin watanni 3 bayan matakin farko na jiyya.Jagororin Accp9 sun fara ba da shawarar sabbin magungunan maganin na baka.A cikin fitowar ta 10 na kwalejin Ba'amural Amurka (ACPP), babbar bambanci daga abin da aka hana halittar kwamfuta (noac), irin su factor, da sauransu) da kuma factor Iia suna hana su ( dabigatran, da sauransu) ana amfani da su azaman zaɓi na farko don maganin VTE.Maganin ciwon huhu yana da tabbataccen tasiri, yana rage rikice-rikicen jini sosai, kuma baya buƙatar sake duba aikin coagulation.Ana ƙara haɓakawa a cikin marasa lafiya na yau da kullun.Sabbin magungunan kashe jini gabaɗaya na iya guje wa maimaita DVT a cikin 80% ~ 92%.

Ƙayyadaddun maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin jini.Ba a cika ganin sharewar thrombus ba a cikin marasa lafiya da ke fama da thrombosis na iliofemoral, kuma ragowar thrombus na iya haifar da lalacewar bawul ɗin venous da toshewar fili, waɗanda sune dalilan da ke haifar da babban abin da ya faru na ciwon bugun jini (PTS).Binciken da aka yi a kan abin da ya faru na PTS bayan DVT maganin rigakafi ya nuna cewa abin da ya faru na PTS ya kasance game da 20% ~ 50%, abin da ya faru na venous ulcer na ƙananan gaɓɓai ya kasance 5% ~ 10%, kuma abin da ya faru na claudication venous shine 40% bayan shekaru 5.Kimanin kashi 15 cikin dari na marasa lafiya suna da matsalolin motsi, kuma an rage yawan rayuwar 100% na marasa lafiya zuwa digiri daban-daban.